cabozantinib,atezolizumab
roche
['renal,(-adrenal)', 'contact-3', 'cabo ', 'atezo', 'cabozantinib']
1/3 contact-3 clearly shows the addition of atezolizumab to cabozantinib is no better than cabo alone in advanced renal cancer patients who have had pd on pd1 therapy. it seems to add to toxicity with no subset benefiting. this approach should be avoided. #asco2023 
Interested in Urology Cancers, biomarkers and drug development.